Sofinnova Group Reduces Stake Below 5% in Vera Therapeutics
Summary
Sofinnova Venture Partners X and its affiliates, including director Dr. Maha Katabi, have reported that their beneficial ownership in Vera Therapeutics has fallen below the 5% threshold, primarily due to dilution from the company's share sales.
Key Events
-
Ownership Below 5%
Sofinnova Venture Partners X and its affiliates now collectively own 3.9% of Vera Therapeutics' common stock, down from a previous stake above 5%.
-
Reason for Reduction
The decrease in percentage ownership is primarily due to dilution from the Issuer's share sales, including a December 2025 offering, and prior open market sales by Sofinnova in March 2024.
-
Director's Continued Involvement
Dr. Maha Katabi, a director of Vera Therapeutics and managing member of Sofinnova Management X-A, L.L.C., continues to hold shares and exercisable options, maintaining a 4.0% beneficial ownership.
Analysis
This Schedule 13D/A filing indicates that Sofinnova Venture Partners X, a significant institutional investor, along with its associated entities and director Dr. Maha Katabi, no longer beneficially own more than 5% of Vera Therapeutics' common stock. This change in status, which occurred as of September 30, 2025, is attributed to dilution from the Issuer's sales of additional shares, including a Form 424(b)(5) offering in December 2025, as well as prior open market sales by Sofinnova in March 2024 totaling approximately $34 million. While the underlying transactions are not new, the official reporting of this reduced stake below the 5% threshold is a notable update for investors tracking institutional support and ownership concentration.
At the time of this filing, VERA was trading at $39.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $18.53 to $56.05. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.